Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies

Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF, TASE: CANF))), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with advanced pancreatic cancer.

The planned Phase 2b study follows encouraging findings from the Company's ongoing Phase 2a study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed following at least one prior line of therapy. The Phase 2a study demonstrated a favorable safety profile together with clinical activity manifested by prolonged treatment duration in a subset of patients including treatment extending beyond 16 months, stable disease observed in >30% of evaluable patients and 35% of patients remain on therapy and follow up.

The upcoming Phase 2b study is expected to evaluate Namodenoson in combination with immunotherapy in order to further assess clinical benefit, including progression-free survival, overall survival, disease stabilization, and additional efficacy endpoints.